1901 W. 47TH PLACE, KANSAS CITY, KS
Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness
Cingulate Inc. Eliminates Chief Legal Officer Position; Nilay Patel Departs
Cingulate Inc. Approves Amendment to 2021 Omnibus Equity Incentive Plan
Added to Russell 3000E®
Issued First U.S. Patent for Lead ADHD Asset CTx-1301
Receives Complete Response Letter from FDA for CTx-1301
Annual Report to Security Holders
Board Restructuring - Jeff Ervin and Jay Roberts Not Seeking Re-Election
Q2
Q1
FY 2025
Q3
Notice of Late Filing for Quarterly Report
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload